Legal Representation
Attorney
Leigh Ann Lindquist
USPTO Deadlines
Next Deadline
517 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-12-29)
Due Date
December 29, 2026
Grace Period Ends
June 29, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
46 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Feb 7, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Nov 28, 2024 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
Apr 24, 2021 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
Apr 1, 2021 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
Apr 1, 2021 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
Mar 29, 2021 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
Dec 29, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Oct 18, 2020 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
Oct 13, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Oct 13, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Sep 30, 2020 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
Sep 30, 2020 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
Sep 23, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Sep 10, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Sep 10, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Sep 10, 2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
Sep 10, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Sep 10, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Aug 21, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Aug 21, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
Aug 21, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Aug 5, 2020 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
Aug 4, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Aug 4, 2020 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
Aug 4, 2020 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
Jun 5, 2020 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
Jun 4, 2020 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
May 28, 2020 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Mar 25, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Mar 25, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Mar 25, 2020 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
Mar 25, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Mar 25, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Mar 25, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Oct 26, 2019 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
Oct 5, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
Oct 5, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
Sep 20, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
Sep 19, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Sep 11, 2019 | RFWR | P | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | Loading... |
Aug 27, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
Aug 26, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Aug 20, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Aug 20, 2019 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
Aug 16, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Aug 8, 2019 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical agents affecting sensory organs; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for the treatment of short bowel syndrome; Pharmaceutical agents for treatment of diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for the treatment of rheumatoid arthritis; vaccines; pharmaceutical preparations for the treatment of anemia; fungicides; anti-inflammatories; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations for the treatment of cardiovascular disorders; medicated candy; Pharmaceutical preparations to treat HPV type 16 and/or 18 caused Precancerous Dysplasia and Cancer; pharmaceutical preparations for the treatment of inflammatory bowel disease; Pharmaceutical preparations being pills for inflammation treatment; pharmaceutical preparations for the treatment of dwarfism; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; pharmaceutical preparations for the treatment of systemic lupus erythematosus; Pharmaceutical agents for treating asthma, Pharmaceutical agents for the treatment of asthma; dermatological pharmaceutical products; antibiotic preparations; antibiotics; anti-cancer preparations; Antibody fusion protein for medical treatment in the nature of pharmaceutical preparations for the treatment of HPV type 16 and/or 18 caused Precancerous Dysplasia and Cancer; blood solvent, namely, blood plasma; pharmaceutical preparations for the treatment of neutropenia
Classification
International Classes
005